StockData
Bicara Therapeutics Inc. logo

Bicara Therapeutics Inc. (BCAX) stock

BCAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$9.75−0.27 (-2.69%)

Close on Nov 16, 2026Market cap $645.19MP/E –Yield –

Bicara Therapeutics cash

Cash and short-term investments held at the end of each period.

Bicara Therapeutics's cash was $442.35M at Sep 30, 2026. For fiscal 2025 it was $414.80M, down 15.3% from the year before.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$414.80M-15.3%
FY2024Dec 31, 2024$489.71M+112.5%
FY2023Dec 31, 2023$230.44M+5442.1%
FY2022Dec 31, 2022$4.16M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$442.35M+52.4%
Q2 FY2026Jun 30, 2026$497.26M+13.9%
Q1 FY2026Mar 31, 2026$539.75M+16.8%
Q4 FY2025Dec 31, 2025$414.80M-15.3%
Q3 FY2025Sep 30, 2025$290.17M-44.3%
Q2 FY2025Jun 30, 2025$436.61M+114.2%
Q1 FY2025Mar 31, 2025$462.07M+113.9%
Q4 FY2024Dec 31, 2024$489.71M+112.5%
Q3 FY2024Sep 30, 2024$520.76M+1077.9%
Q2 FY2024Jun 30, 2024$203.86M+4802.7%
Q1 FY2024Mar 31, 2024$216.05M–
Q4 FY2023Dec 31, 2023$230.44M–
Q3 FY2023Sep 30, 2023$44.21M–
Q4 FY2022Dec 31, 2022$4.16M–

More Bicara Therapeutics figures

See a number that looks wrong?